rheumnow.com
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening…
ard.bmj.com
It appears that far lower doses of Rituximab than what is currently given, albeit at shorter intervals, can deplete B-cells to an equivalent degree and duration. Preliminary clinical studies suggest that such low dose regimens are as effective in maintaining disease remission in AAV, RA and other connective tissue diseases. If indeed so, this can eventually translate to tremendous cost savings and better safety.